Short cuts

Epirubicin improves classic chemotherapy for early breast cancer

BMJ 2006; 333 doi: 10.1136/bmj.333.7576.1014-c (Published 9 November 2006)
Cite this as: BMJ 2006;333:1014.4

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Adjuvant chemotherapy reduces the risk of cancer recurrence and prolongs survival in women with early breast cancer. Traditional regimens of cyclophosphamide, methotrexate, and fluorouracil (CMF) have been around since the 1970s, but it's now clear that regimens including an anthracycline such as epirubicin work …

Access to the full text of this article requires a subscription or payment

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL